The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria
Floridas SB 860 targets weight-loss drugs specifically, requiring you to certify that your API is identical to the approved drug and sourced from a facility inspected within the last two years
They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain
Constipation : Conversely, others may face constipation due to slowed gut movement
GLP-1 use surges Big picture view: The findings come as policymakers and insurers grapple with the growing demand for GLP-1 drugs
